|
Oxford BioDynamics PLC on Thursday said it is planning to apply for inclusion into the National Comprehensive Cancer Network clinical guidelines, as it reported the publication of interim results from its FDA-registered Prowes trial. The Oxford, England-based biotechnology company that develops medical tests said the study demonstrates the ‘clinical utility’ and ‘treatment impact’ of EpiSwitch Cirt, its checkpoint inhibitor response test. The study was published in the medical journal Cancers. Oxford BioDynamics noted that the peer-reviewed publication of the ongoing study looked at the clinical utility of its blood test in guiding treatment decisions for 205 patients receiving immune checkpoint inhibitors across an array of advanced solid tumours. The company said findings showed that oncologists’ treatment choices were influenced in 61% of cases by Cirt. This included decisions to avoid therapy, initiate, escalate or deescalate it, Oxford BioDynamics said. Shares in Oxford BioDynamics rose 16% to 0.52 pence on Thursday afternoon in London. The study also demonstrated that results were closely tied to real world patient outcomes, said Oxford BioDynamics, and possessed broad applicability. ‘These findings underscore Cirt’s potential to personalise care pathways, improve patient outcomes and deliver significant cost efficiencies,’ the company said. ‘The Prowes results represent a significant milestone that further validates the transformative real-world impact of the EpiSwitch Cirt test on decision-making in real clinical practice,’ said Thomas Guiel, chief operating officer at Oxford BioDynamics. ‘These results not only strengthen the scientific foundation of Cirt, but also support our strategy to secure inclusion in NCCN (National Comprehensive Cancer Network) clinical guidelines. The company expects to apply for inclusion later this year, which is a critical step towards driving widespread adoption and achieving our commercial objectives,’ continued Guiel. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
